Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Assets Average (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Assets Average for 8 consecutive years, with $213.9 million as the latest value for Q4 2024.

  • On a quarterly basis, Assets Average fell 10.26% to $213.9 million in Q4 2024 year-over-year; TTM through Dec 2024 was $213.9 million, a 10.26% decrease, with the full-year FY2024 number at $231.2 million, down 22.65% from a year prior.
  • Assets Average was $213.9 million for Q4 2024 at Akebia Therapeutics, down from $233.6 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $779.5 million in Q1 2020 to a low of $213.9 million in Q4 2024.
  • A 5-year average of $490.1 million and a median of $535.7 million in 2022 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: crashed 50.11% in 2023, then fell 10.26% in 2024.
  • Akebia Therapeutics' Assets Average stood at $660.1 million in 2020, then fell by 14.29% to $565.8 million in 2021, then dropped by 29.28% to $400.2 million in 2022, then plummeted by 40.44% to $238.4 million in 2023, then dropped by 10.26% to $213.9 million in 2024.
  • Per Business Quant, the three most recent readings for AKBA's Assets Average are $213.9 million (Q4 2024), $233.6 million (Q1 2024), and $238.4 million (Q4 2023).